RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Poll|Articles|April 2, 2024
Have You Seen the Translating Research Into Practice Column?
Author(s)Psychiatric Times Editors
Have you checked out the latest Translating Research Into Practice column? Let us know!
Advertisement
The Translating Research Into Practice (TRIP) column, edited by Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP, is dedicated to reviewing the literature and sharing clinical implications.
Did you read the first installment, "Exploring the Role of Brexpiprazole in Alzheimer Dementia Agitation"?
If not, check it out here:
Did you read the second installment, "Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease"?
If not, check it out here:
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Evidence-Based Pharmacologic Approaches to Reducing Suicide Risk
2
Dissecting Algorithms of the Mind: Toward Precision Psychiatry in Schizophrenia
3
Fewer Than 1 in 5 Young Patients With First-Episode Psychosis Adhere to Antipsychotics
4
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
5